A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2

Celine M. Vachon, Daniel J. Schaid, James N. Ingle, D. Lawrence Wickerham, Michiaki Kubo, Taisei Mushiroda, Matthew P. Goetz, Erin E. Carlson, Soonmyung Paik, Norman Wolmark, Yusuke Nakamura, Liewei Wang, Richard Weinshilboum, Fergus J. Couch

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case–control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 % increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (Pintx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (Pintx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.

Original languageEnglish
Pages (from-to)517-523
Number of pages7
JournalBreast Cancer Research and Treatment
Volume149
Issue number2
DOIs
Publication statusPublished - 01-01-2015
Externally publishedYes

Fingerprint

Tamoxifen
Breast Neoplasms
Selective Estrogen Receptor Modulators
Raloxifene Hydrochloride
Single Nucleotide Polymorphism
Genotype

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Vachon, Celine M. ; Schaid, Daniel J. ; Ingle, James N. ; Wickerham, D. Lawrence ; Kubo, Michiaki ; Mushiroda, Taisei ; Goetz, Matthew P. ; Carlson, Erin E. ; Paik, Soonmyung ; Wolmark, Norman ; Nakamura, Yusuke ; Wang, Liewei ; Weinshilboum, Richard ; Couch, Fergus J. / A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. In: Breast Cancer Research and Treatment. 2015 ; Vol. 149, No. 2. pp. 517-523.
@article{cb7d3e58ce964bfdb024ea209f95da16,
title = "A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2",
abstract = "Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case–control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 {\%} increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (Pintx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (Pintx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.",
author = "Vachon, {Celine M.} and Schaid, {Daniel J.} and Ingle, {James N.} and Wickerham, {D. Lawrence} and Michiaki Kubo and Taisei Mushiroda and Goetz, {Matthew P.} and Carlson, {Erin E.} and Soonmyung Paik and Norman Wolmark and Yusuke Nakamura and Liewei Wang and Richard Weinshilboum and Couch, {Fergus J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s10549-014-3175-4",
language = "English",
volume = "149",
pages = "517--523",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

Vachon, CM, Schaid, DJ, Ingle, JN, Wickerham, DL, Kubo, M, Mushiroda, T, Goetz, MP, Carlson, EE, Paik, S, Wolmark, N, Nakamura, Y, Wang, L, Weinshilboum, R & Couch, FJ 2015, 'A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2', Breast Cancer Research and Treatment, vol. 149, no. 2, pp. 517-523. https://doi.org/10.1007/s10549-014-3175-4

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. / Vachon, Celine M.; Schaid, Daniel J.; Ingle, James N.; Wickerham, D. Lawrence; Kubo, Michiaki; Mushiroda, Taisei; Goetz, Matthew P.; Carlson, Erin E.; Paik, Soonmyung; Wolmark, Norman; Nakamura, Yusuke; Wang, Liewei; Weinshilboum, Richard; Couch, Fergus J.

In: Breast Cancer Research and Treatment, Vol. 149, No. 2, 01.01.2015, p. 517-523.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2

AU - Vachon, Celine M.

AU - Schaid, Daniel J.

AU - Ingle, James N.

AU - Wickerham, D. Lawrence

AU - Kubo, Michiaki

AU - Mushiroda, Taisei

AU - Goetz, Matthew P.

AU - Carlson, Erin E.

AU - Paik, Soonmyung

AU - Wolmark, Norman

AU - Nakamura, Yusuke

AU - Wang, Liewei

AU - Weinshilboum, Richard

AU - Couch, Fergus J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case–control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 % increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (Pintx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (Pintx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.

AB - Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case–control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 % increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (Pintx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (Pintx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.

UR - http://www.scopus.com/inward/record.url?scp=84921924002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921924002&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3175-4

DO - 10.1007/s10549-014-3175-4

M3 - Article

VL - 149

SP - 517

EP - 523

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -